Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 12, 2024
Daily News
June 12, 2024
- En Route to 2030 Target, Shionogi to Carve Out New Biz in Areas with High Medical Needs
June 12, 2024
- Otsuka Resolved to Log 2.5 Trillion Yen in FY2028 by Offsetting Patent Cliffs with Novel Drugs
June 12, 2024
- Social Security Budget Ceiling Looks Set to Continue 3 More Years: Honebuto Draft
June 12, 2024
- Honebuto Draft Equivocal on Off-Year Price Cuts, but Focuses on FY2025 Revision
June 12, 2024
- Label Revisions Ordered for Brimonidine, Finerenone, and More
June 12, 2024
- Kyowa Kirin to Build Biologics Manufacturing Site in North Carolina
June 12, 2024
- Maruho Launches Mitchga 30 mg Vial Version in Japan
June 12, 2024
- US FDA Snubs Mitsubishi Tanabe’s Parkinson’s Drug
June 12, 2024
- Akira Endo, Who Pioneered Discovery of Statins, Dies at 90
June 12, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…